Median progression-free survival was 160 months ( 95 % CI 139-181 ) with erlotinib plus bevacizumab and 97 months ( 57-111 ) with erlotinib alone ( hazard ratio 054 , 95 % CI 036-079 ; log-rank test p = 00015 ) .